Mani Mohindru, Chief Executive Officer at Cardiff Oncology, Inc. (CRDF), bought 34,364 shares at $1.46 ($50K) on 2026-07-14, disclosed to the SEC on 2026-07-16.
CEO Mani Mohindru purchased 34,364 shares at $1.46, marking the largest purchase of his career, as the stock trades near its 52-week low. The buy comes amidst a leadership transition and the company's pursuit of a $10 million registered direct offering to bolster working capital.
CRDF is down 32.77% over the past 5 days and 50.69% over the last 90 days, trading at $0.8875, which is just 6.77% above its 52-week low of $0.8312.
The company announced a $10 million registered direct offering on July 15, 2026, to strengthen working capital; the 30mg onvansertib regimen is advancing toward a 2026 registrational mCRC study announced on January 27, 2026; and interim data showing a 72% ORR in Phase II RAS-Mutant mCRC was presented on March 25, 2026.
Short interest remains elevated at 19.19% of the float, and Lucid Capital analyst Christopher Liu reduced the price target to $4 on June 30, 2026.
Something here stands out, but not much.
| Filing → |
| CARA | SELL | 2019-07-17 | $936K | — | Filing → |
| CARA | SELL | 2019-05-30 | $107K | — | Filing → |
| CARA | SELL | 2019-03-15 | $613K | — | Filing → |